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Diffuse intrinsic pontine glioma (DIPG) is a deadly paediatric brain cancer. Transient response to radiation, ineffective chemothera-
peutic agents and aggressive biology result in rapid progression of symptoms and a dismal prognosis. Increased availability of 
tumour tissue has enabled the identification of histone gene aberrations, genetic driver mutations and methylation changes, which 
have resulted in molecular and phenotypic subgrouping. However, many of the underlying mechanisms of DIPG oncogenesis re-
main unexplained. It is hoped that more representative in vitro and preclinical models–using both xenografted material and geneti-
cally engineered mice–will enable the development of novel chemotherapeutic agents and strategies for targeted drug delivery. 
This review provides a clinical overview of DIPG, the barriers to progress in developing effective treatment, updates on drug devel-
opment and preclinical models, and an introduction to new technologies aimed at enhancing drug delivery.
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INTRODUCTION
Diffuse intrinsic pontine gliomas (DIPG) are paediatric high-
grade gliomas (pHGG) characterised by infiltrative tumours of 
the brainstem. DIPGs are histologically astrocytomas, have a 
peak onset of 6–9 years (adolescents and adults can also be af-
fected) and account for 10–20% of all paediatric brain tu-
mours45). DIPGs are the leading cause of brain tumour deaths 
in children33). Median overall survival (OS) is between 8 to 12 
months, and OS is approximately 30% at 1 year, 10% at 2 years 
and less than 1% at 5 years from diagnosis23,45,49,51). The combi-
nation of a short clinical history (<6 months) and typical ap-
pearances on magnetic resonance imaging (MRI) are usually 
diagnostic21). Neurological symptoms can vary based on the 
extent and specific location of the lesion within the pons but 
over 50% present with the classical triad of cranial nerve defi-
cits (facial asymmetry and diplopia), cerebellar signs (ataxia, 
dysmetria, and dysarthria) and long tract signs (hyperreflexia, 
upward Babinski and decreased strength)54). A highly sensitive 
predictor of DIPG is a primary presentation of abducens palsy 
in a young child20). In the absence of an exophytic component 
that extends posteriorly to cause obstructive hydrocephalus 
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(<10%), raised intracranial pressure is usually not observed. 
DIPG tumours can spread along fiber tracts to local sites such 
as the cerebellum and thalamus but rarely metastasise to dis-
tant sites.
Radiation is the only treatment with proven efficacy (albeit 
limited) in prolonging progression-free survival (PFS)64). It can 
also provide transient symptomatic improvement and im-
proved neurologic function33). The current radiotherapy dose in 
children with DIPG is typically 54 Gy (54/1.8 Gy) over 6 weeks67). 
A shorter hypofractionated radiation therapy regimen deliver-
ing 39 Gy (39/3 Gy) over 13 days has been proposed for newly 
diagnosed DIPG as it was shown to lessen the treatment bur-
den whilst being non-inferior to conventional radiotherapy 
(54/1.8 Gy) with respect to OS and PFS29).
There are currently no proven chemotherapeutic agents that 
have been shown to increase PFS or OS51). Numerous clinical 
trials aimed at investigating existing alkylating agents (e.g., 
cisplatin, temozolomide, carboplatin), alone or neo-adjuvant 
to radiation, have failed2,13,28). Agents targeting other biologic 
and molecular pathways, such as erlotinib (EGFR inhibitor), 
tamoxifen (oestrogen-receptor modifier) and bevacizumab 
(VEGF inhibitor) have also been shown to be ineffective, alone 
or in combination with radiotherapy33,44). Radiosensitisers such 
as carbogen and motexafin gadolinium also have no proven 
survival benefit1,7).
In part, these failures have been due to a poor understanding 
of the underlying molecular and cellular biology, an underap-
preciation of the tumour heterogeneity (paucity of primary 
tissue), and a lack of representative in vitro and in vivo mod-
els23). Many trials have also failed due to a long-held assump-
tion that the biological properties of paediatric DIPGs are 
similar to adult high grade gliomas (HGG)35,50). It is becoming 
increasingly clear however, that DIPG differs markedly from 
adult HGG, and even from supratentorial pHGG, at a pheno-
typic and molecular level11,35). 
This review aims to outline ongoing and historical barriers 
to advancing treatment, provide an overview of molecular pro-
filing and preclinical models, and appraise the latest research 
into novel chemotherapeutic agents and advances in enhanced 
drug delivery technologies–including, but not limited to, mag-
netic resonance guided focused ultrasound (MRgFUS). 
SIGNIFICANT BARRIERS TO PROGRESS
Significant challenges exist in DIPG management. Principal 
to this is the eloquent brainstem location of the tumour which 
results in unacceptable risks of morbidity and mortality from 
surgical debulking. Aligned with this, the infiltrative nature of 
the tumour makes complete resection impossible. Additionally, 
the absence of effective drug treatment that changes the natu-
ral history of the disease, and hallmark imaging suggest that 
even biopsy offered little diagnostic or therapeutic advantage to 
the patient. The lack of primary tissue from either biopsy or deb-
ulking has contributed to the longstanding poor understand-
ing of the underlying biology and a lack of representative exper-
imental model systems23). However, there has been an increased 
tendency more recently to perform stereotactic biopsy as it has 
been shown to be a minimally morbid procedure with high di-
agnostic yield9,52). Most centres would support a biopsy in sus-
pected DIPG patients with atypical imaging and/or in the con-
text of an approved clinical trial where tissue would help 
stratify participants into trial arms51,63). In addition to more post-
mortem tissue donations, the increased quantity and quality of 
fresh biopsy tissue has enabled a number of molecular studies 
to be performed robustly and reproducibly45), and preclinical 
models to be developed32). Biological information gleaned from 
biopsy tissue has also informed clinical trial treatment regi-
mens3).
MRI in DIPG typically reveals a T1 hypointense, T2 hyper-
intense tumour centred in and involving >50% of the pons, 
with associated signal change (Fig. 1). Perhaps most interest-
ingly, and not in keeping with other HGGs, there is absent or 
irregular contrast enhancement25,47). This implies a preserva-
tion of the blood-brain barrier (BBB). It may also explain, in 
part, why chemotherapeutic agents previously shown to be ef-
fective in other gliomas have failed in DIPG–although there 
are surely also biological differences60). Therefore, improving 
drug delivery, either through structural adaptation of drugs or 
disruption of the BBB itself, are required in DIPG if sufficient 
intratumoural doses are to be achieved.
MOLECULAR CLASSIFICATION AND SUBGROPING
Recent identification of a specific point mutation in H3F3A 
(encoding histone 3.3) and HIST1H3B (encoding histone 3.1) 
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genes–leading to the substitution of a lysine by a methionine at 
position 27 (K27M)–has enabled the molecular classification 
of DIPGs11,34,65). A profound epigenetic change was found to oc-
cur in 95% of DIPG samples with the H3-K27M mutation, 
shown to be due to impaired function of polycomb repressive 
complex 2 (PRC2) methyltransferase. The result is global hy-
pomethylation of H3K275,12). The H3-K27M mutation was used 
to define a new entity in the most recent 2016 World Health Or-
ganization classification of central nervous system tumours35). 
Recent epigenetic data have shown that despite a major reduc-
tion in trimethylation of H3K27 secondary to impaired PRC2 
function, some residual PRC2 activity is maintained in DIPG 
cells and may in fact be required to repress neuronal differenti-
ation and function, ultimately maintaining cellular prolifera-
tion48). This complicates the biology somewhat but potentially 
exposes another therapeutic target.
Patients with tumours carrying a H3F3A mutation had a sig-
nificantly poorer response to radiotherapy, relapsed earlier and 
had more metastatic recurrences than those with HIST1H3B 
mutations11). This pro-metastatic H3F3A cohort was character-
ised by increased PDGFRA gene expression and a proneural/
oligodendroglial phenotype whereas the HIST1H3B genotype 
was characterised by a pro-angiogenic/hypoxic gene expression 
signature and a mesenchymal/astrocytic phenotype11). The 
HIST1H3B and H3F3A mutations are mutually exclusive. Such 
an improved understanding of the differences in the natural 
history of DIPG molecular subtypes has proven very useful to 
clinicians in prognosticating, and empowering patients.
In addition to the histone 3 variant mutations, other recur-
rent driver mutations have also been identified. Mutations in 
the ACVR1 gene exist concurrently with H3 mutations in 20–
30% of DIPGs8). This mutation has been shown to ultimately 
upregulate the bone morphogenetic protein developmental 
signalling pathway59). It is not directly clear what the role of the 
ACVR1 mutation is in DIPG oncogenesis. Mutations in TP53, 
a known tumour suppressor gene, exists in up to 77% of DIP-
Gs54). A further important genetic aberration in DIPG involves 
amplification of components of the receptor tyrosine kinase/
Ras/phosphatidylinositol-3 pathway, especially platelet-derived 
growth factor receptor A (PDGFRA)54).
Recently, three molecular subgroups–MYCN, Silent and 
H3K27M–have been defined by integrating DNA methylation 
analyses, whole genome sequencing, histopathological and 
clinical data8). The MYCN subgroup is characterised by high-
grade histology, chromothripsis (thousands of chromosomal 
rearrangements occurring as a single event in localised and con-
fined regions) on chromosome 2p, and DNA hypermethylation. 
The Silent subgroup is characterised by a lower genomic muta-
tional burden than the other 2 subgroups. The H3K27M sub-
group is the most prevalent in DIPG and is characterised by the 
histone mutations above, as well as by global DNA hypometh-
ylation and multiple concurrent mutations (TP53, PAX3, PG-
FRA, EGFR, ATRX, NF1, PPM1D, PIK3CA, TERT, NTRK, IL-
13RA2, PARP1, PTEN, CCND1/2/3, CDK4/6 and MET)45).
The current understanding between the interrelated DIPG 
subgroups is shown in Fig. 2. Perhaps most importantly, it is 
Fig. 1. Magnetic resonance imaging (T2) showing lesion expanding the pons 
(white arrow), with associated signal change.
Fig. 2. DIPG subgrouping map showing the current understanding between 
the interrelated DIPG subgroups (adapted from Misuraca et al.41)). DIPG : dif-
fuse intrinsic pontine glioma.
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hoped that such molecular classification and subgrouping will 
identify distinct cellular origins and biological drivers of tu-
morigenicity that will lead to effective DIPG-specific thera-
pies31). 
PRECLINICAL MOUSE MODELS OF DIPG
The identification of recurrent driver mutations has enabled 
the development of preclinical mouse models. As with all mod-
els, strengths and caveats exist, but work in other cancers has 
demonstrated that validated preclinical models are essential in 
drug screening and the development of novel therapeutics. 
There are now well established orthotopic xenograft and ge-
netically engineered mouse models (GEMMs) of DIPG. 
The earliest preclinical models used cell-derived orthotopic 
xenografts (CDOXs) and patient-derived orthotopic xenografts 
(PDOXs) from autopsy tissue. CDOX models were generated 
by stereotactic intracranial injection of tumour-initiating cells 
cultured from DIPG autopsy tissue harbouring the H3K27M 
driver mutation43). The advantage of a CDOX model is that the 
cells can be manipulated to express luciferase and tagged with 
fluorescent reporter proteins, allowing for longitudinal tumour 
growth monitoring and cell tracing, respectively. 
PDOX models have been developed more recently from di-
rect injection of autopsy DIPG cells32). The advantage of devel-
oping PDOX models is that the cells are not subject to the clonal 
selective pressures exerted by in vitro cell culture. Both these 
CDOX and PDOX models showed the characteristic DIPG in-
filtrative phenotype. The disadvantage of both models is that 
autopsy tissue is not treatment-naïve. This means that the mod-
els may not be representative of the patient at the time of pre-
sentation. To exemplify this, the average mutation rate detected 
at the time of autopsy is 3.12 somatic mutations per megabase8) 
while it is 0.76 at diagnosis59). Recently, a group aimed to over-
come this by developing preclinical models (both CDOX and 
PDOX) using treatment-naïve fresh tissue attained at the time 
of diagnostic biopsy49). These models more faithfully recapitu-
late the histological and MRI features seen in DIPG patients at 
the time of diagnosis. They also demonstrate a typically invasive 
phenotype, harbour the H3K27M trimethylation loss genotype 
in vivo and cover more of the spectrum of histone modifica-
tions and lineage markers observed in patients. Moreover, the 
mice presented with neurological symptoms and a natural his-
tory similar to that observed in DIPG patients. One previous 
problem with using xenografted DIPG tissue had been the de-
velopment of malignant murine tumours rather than human 
tumours10). These latest models do not develop such tumours, 
representing an advancement on previous DIPG preclinical 
models. The results of future studies using these models, and 
their translational to clinical practice, will ultimately determine 
their true value.
The development of models using treatment-naïve and au-
topsy tissue is complementary–the former allowing for testing 
of strategies more applicable to the early stages of the disease, 
whilst the latter is more ideal for the end stages of DIPG, recur-
rence and resistance49). Moving from one to the other also has 
the potential to better delineate the evolution of the disease.
Another class of preclinical models, GEMMs, work on the 
principle of introducing a limited number of genetic alterations 
to induce in vivo oncogenesis. The advantage of these models 
is the ability to study tumours arising in the natural environ-
ment of immune-proficient animals (CDOX and PDOX ani-
mal models must be immune-deficient to prevent rejection of 
the xenografted material). One such model that shows promise 
in DIPG is the replication-competent avian sarcoma–leucosis 
virus long terminal repeat with splice acceptor/tumour virus 
A (RCAS-Tva) system61). This system can produce brainstem 
tumours that harbour the three most common genetic aberra-
tions observed in DIPG–H3K27M, TP53 and PDGFRA4). This 
model has been used to study a multi-kinase inhibitor (BMS-
754807) but no survival benefit was shown24). It is difficult to 
evaluate the drug’s effectiveness against the tumour biology, 
however, since the authors identified that drug delivery was be-
low the known IC-50 (the concentration of an inhibitor at 
which response is reduced by half)–most likely due to BBB im-
permeability.
The RCAS-Tva GEMM has also been used to study the in vivo 
biology of DIPG. In contrast to supratentorial glioma, high lev-
els of PAX3 expression have been implicated in the oncogenesis 
of brainstem gliomas such as DIPG40). This has further defined 
a new subset of DIPG and subsequently a novel mouse model 
that aims to represent this genotype41,42).
Another new development in DIPG modelling uses neural 
progenitors (derived from human pluripotent stem cells) co-
transduced in vitro with common DIPG alterations (PDGFRA, 
TP53 and H3F3A)22). These cells can then be studied in vitro or 
transplanted into rodents, and the resultant oncogenesis studied.
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Recently, a group has used electroporation to transduce mouse 
brainstem neural progenitor cells with K27M DNA in utero46). 
The resultant progeny developed highly proliferative, diffusely 
spreading lesions that had the hallmark molecular and histo-
pathological features of pHGG. These tumours could then be 
serially engrafted in recipient mice and used for targeted drug 
screening. This novel mouse model might provide insights into 
in utero drivers of neurodevelopmental change that result in 
oncogenic transformation to pHGG postnatally.
In terms of xenograft material delivery, there have also been 
developments on the technical side of preclinical models in 
DIPG. A recent publication replaced the stereotactic frame tra-
ditionally used to deliver cells into CDOX and PDOX models 
with a guide-screw bolt36). The main advantage of this tech-
nique is the ability to leave the bolt in place and use it as a con-
duit for delivery of intratumoural chemotherapy, antibodies, and 
gene or viral therapies.
Clearly much progress has been made in DIPG preclinical 
modelling, but developments are still required to represent oth-
er oncogenic drivers such as ACVR1 and MYCN to fully cover 
the subtypes. 
NOVEL CHEMOTHERAPEUTIC AGENTS
Building on the increased knowledge of the H3K27M DIPG 
epigenetic landscape, members of the bromo- and extra-termi-
nal (BET) domain family have been shown to be important in 
the role of translating the hypomethylation changes into a dis-
ease phenotype48). By targeting this relationship, a recent study 
using a BET inhibitor (JQ1) to treat mice xenografted with hu-
man DIPG H3K27M cell lines showed tumour regression48). 
Furthermore, BET inhibitors have been shown to cross the BBB.
There have also been promising results investigating the 
multi-histone deacetylase inhibitor panobinostat, alone and 
in combination with the histone demethylase inhibitor GSK-
J4, in patient-derived DIPG in vitro and orthotopic xenograft 
models23,26).
Another approach investigated the reactivation of p16 (CD-
KN2A), a tumour suppressor gene that has been shown to be 
inactivated in the H3F3A subgroup of DIPG patients. The study 
showed that the administration of a DNA methylation inhibi-
tor restored p16 levels with resultant cytotoxicity to murine tu-
mour cells14). Clinical trials are now required to investigate all 
these approaches further.
Since PDGFRA is one of the most frequent mutations in 
DIPG, its downstream effector pathway PI3K/AKT/mTOR has 
been targeted with single agents66). However, this has proved in-
effective, primarily due to the development of resistance. The 
latter was linked to activation of the related Ras/Raf/MEK/ERK 
pathway. Therefore, combinatorial therapy (perifosine–a PI3K/
AKT inhibitor and trametinib–a MEK inhibitor) targeting both 
pathways has recently been tested66). Results show a reduction in 
in vitro cell viability. Validation in vivo and progression to clini-
cal trials is now required. In a separate phase I trial recently re-
ported, perifosine was combined with temsirolimus (an mTOR 
inhibitor) to treat a range of recurrent and refractory paediatric 
high-grade solid tumours, DIPG amongst them. Results show 
that this combination was generally well tolerated, with no dose 
limiting toxicity i.e., safe and feasible. Further trials will inves-
tigate efficacy. 
BIOMARKER DISCOVERY
There are currently no clinically validated biomarkers in pae-
diatric or adult gliomas that enable non-invasive screening, treat-
ment response monitoring, or detection of recurrence. In DIPG 
patients, the tumour-associated proteins cyclophilin A and di-
methylarginase 1 have been identified in the cerebrospinal flu-
id. They are both upregulated when compared to controls53). 
Early results from the same authors show that these proteins 
may also be expressed in serum and urine, but the numbers 
studied were low. Further work is required to validate these re-
sults in larger numbers, and prove the sensitivity and specific-
ity required to develop these findings into a clinically useful 
biomarker.
ADVANCES IN DRUG DELIVERY
Convection-enhanced delivery (CED) is a technique first es-
tablished in the 1990s that aims to bypass the BBB by deliver-
ing drugs directly to their intended target6). It relies on accurate 
surgical placement of a microcatheter (or multiple microcathe-
ters) directly into the tumour. The catheter(s) are connected to 
a pump which exerts a small, repetitive hydraulic pressure that 
delivers the drug in solution68). CED with various therapeutic 
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agents have been trialled numerous times in patients with su-
pratentorial high-grade gliomas, with some success68). As DIPG 
is a relatively compact tumour and has no definitive treatment, 
it is an attractive option for evaluating CED. In vivo safety of 
CED has been established in both small and large animals. This 
led to a phase I trial of CED of124I-8H9 radio-labelled monoclo-
nal antibody in children with DIPG that had been previously 
irradiated58). This study demonstrated that CED is well tolerat-
ed and safe. Subsequently, there are now a few clinical trials in 
progress of brainstem CED in children with DIPG using tar-
geted macromolecules such as antibodies and immunotoxins. 
There is also an ongoing neurosurgical trial (Memorial Sloan 
Kettering Cancer Center and Weill Cornell Medical College, 
trial number NCT01502917) evaluating a neuronavigational 
tool (iPlan Flow, BrainLAB AG, Feldkirchen, Germany) specif-
ically designed to work with CED microcatheter placement in 
the brainstem. 
MRgFUS (Fig. 3A) has its origins in high intensity focused 
ultrasound (HIFU), a modality that is routinely used in ablative 
procedures to treat diseases such as Parkinson’s disease and es-
sential tremor17,38). In the presence of intravenously administered 
microbubbles, and with a lower frequency of ultrasound than 
used in HIFU, MRgFUS can be used to permeabilise the BBB 
without lasting tissue injury19,27,37). The preformed microbubbles 
reduce the extent of BBB tissue damage by 1) limiting the in-
teraction between the endothelial cells and the sonic waves, and 
2) allowing for a lower amount of acoustic energy30,62). MRg-
FUS exerts several mechano-biological effects on the micro-
bubbles, including inertial cavitation, oscillation, and growth 
(Fig. 3B). This, in turn, results in shock waves and acoustic stream-
ing that increase surrounding shear stress39). It is not entirely 
clear which of these mechanisms is more important in BBB dis-
ruption, or the underlying molecular changes that occur at a 
cellular level, but the resultant increase in paracellular transport 
and transcellular active transport provide a window of oppor-
tunity (around 4–6 hours) for drug delivery55-57) (Fig. 3C). MRg-
FUS enhanced delivery has been shown to significantly increase 
brain intratumoural drug concentrations and concomitantly 
increased cell death in preclinical models15,18,19). We have recently 
demonstrated that MRgFUS and microbubble disruption of 
the BBB is both safe and feasible (manuscript under review); in 
addition, this technique is efficacious in concentrating cisplat-
inum concentrations within the pons. Aside from acting as an 
adjuvant delivery mechanism, MRgFUS may also enable repur-
Fig. 3. A : Magnetic resonance guided focused ultrasound preclinical system. B : Schematic 
of focused ultrasound (FUS) delivery causing temporary breach of blood-brain barrier with-
in tumour. C : Schematic of FUS eﬀect on microbubbles within blood vessel and resultant 
breach of BBB allowing delivery of gold nanoparticles (GNPs). MRI : magnetic resonance im-
aging , BBB : blood-brain barrier.
A
C
B
Diffuse Intrinsic Pontine Glioma | Mathew RK, et al.
349J Korean Neurosurg Soc 61 (3) : 343-351
posing of BBB impermeable drugs known to work in other can-
cers, and the administration of higher local doses whilst mini-
mising adverse systemic toxicity16). 
CONCLUSION
DIPG is a fatal childhood brain cancer that has devastating 
consequences for patients, their caregivers and families. De-
spite decades of clinical trials and research, little or no progress 
has been made in improving the lives of affected patients, or 
changing the natural history of the disease. Recent advances in 
molecular profiling techniques allied to increased availability 
of tissue through post-mortem donation and biopsy has signif-
icantly improved our understanding of the origin and biologi-
cal features of DIPG. This has enabled the field to move from 
a purely histology-based characterisation to a more sophisti-
cated molecular-based classification and subgrouping. The 
discovery that the majority of DIPG tumours have epigenetic 
dysregulation as a result of histone mutations has meant that 
epigenetic modifying agents are emerging as a promising class 
of therapeutic agents5,23,26). More work is required to identify and 
validate these mechanisms as effective therapeutic targets. There 
also remain a significant portion of DIPGs that do not carry 
histone or ACVR1 mutations. Further molecular profiling is re-
quired to identify the driver mutational signature underlying 
this Silent subgroup. Ongoing efforts to develop new in vitro 
and preclinical models to represent this subgroup will hopefully 
bring forward new information. Aside from the novel chemo-
therapeutic agents currently under evaluation, perhaps the most 
exciting developments are in the field of enhanced drug deliv-
ery. Advances in ultrasound and convection technology show 
significant promise in overcoming a long-held obstacle to effec-
tive drug targeting of DIPG–the BBB. Establishing a clinically 
proven enhanced drug delivery system, such as MRgFUS, will 
enable drug repurposing screens and the re-evaluation of drugs 
that have previously failed in clinical trials–perhaps due to poor 
target IC-50. Given the significant recent advances in other tu-
mours that for many years were also therapeutically stagnant, 
such as medulloblastoma, there is renewed hope that DIPG is 
on the verge of a new, more promising era.
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